Skip to main content

Table 3 Immunosuppressive treatment during the observation period

From: Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis

 

Non-OC

OC

P value

Baseline

(n = 54)

(n = 17)

 

 Prednisolone (mg/kg/day)

0.91 (0.69–1.15)

1.01 (0.86–1.23)

0.109

3rd month

(n = 49)

(n = 16)

 

 Prednisolone (mg/kg/day)

0.34 (0.27–0.40)

0.31 (0.24–0.40)

0.537

 Cumulative dose of prednisolone (g)

1.6 (1.4–1.8)

1.8 (1.6–1.9)

0.312

 Use of immunosuppressants [n (%)]

7 (14.3)

4 (25.0)

0.309

6th month

(n = 47)

(n = 12)

 

 Prednisolone (mg/kg/day)

0.24 (0.2–0.30)

0.21 (0.21–0.30)

0.605

 Cumulative dose of prednisolone (g)

2.6 (2.2–3.0)

2.5 (2.2–3.0)

0.936

 Use of immunosuppressants [n (%)]

9 (19.1)

3 (17.6)

0.811

1st year

(n = 39)

(n = 10)

 

 Prednisolone (mg/kg/day)

0.18 (0.13–0.20)

0.19 (0.16–0.28)

0.189

 Cumulative dose of prednisolone (g)

3.5 (2.9–4.0)

3.2 (2.6–3.8)

0.442

 Use of immunosuppressants [n (%)]

10 (25.6)

4 (40.0)

0.517

2nd year

(n = 28)

(n = 6)

 

 Prednisolone (mg/kg/day)

0.15 (0.12–0.18)

0.17 (0.13–0.25)

0.320

 Cumulative dose of prednisolone (g)

4.8 (3.7–5.9)

3.9 (2.7–6.2)

0.473

 Use of immunosuppressants [n (%)]

9 (32.1)

4 (66.7)

0.474

  1. Median (interquartile range), categorical values are expressed as number (proportion)
  2. For continuous variables, the Wilcoxon rank-sum test was performed to assess the significance of inter-group differences
  3. Categorical variables were expressed as percentages and compared by using Fisher’s exact test